Search for: "In re Bartlett" Results 41 - 60 of 437
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
11 Mar 2014, 5:49 am by Brad Kaplan
Recently, theNew York Times highlighted examples of re-purposing which are on-going throughout the country. [read post]
5 Jun 2013, 5:29 pm by Allison Tussey
Between January 2008 and January 2009, Bartlett allegedly used SSB Re to sell properties at inflated sales prices to buyers that he knew were fraudulently qualified for mortgage loans. [read post]
On this episode of the Powered podcast, we are joined by Erin Bartlett to bring some clarity and highlight common traps for the unwary. [read post]
2 Aug 2008, 11:10 am
If you're interested in the general topic, it's definitely worth a read.Read more Andrew's post here and check out Peter Black AM here. [read post]
22 Jan 2007, 6:19 pm
With New York's Simpson Thacher & Bartlett pushing first-year base pay to $160,000 -- and seventh years to $265,000 -- will other California-based firms be forced to follow suit? [read post]
1 May 2014, 4:59 am
            So we read the decision in In re: Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (Gannon), No. 3:13-cv-10143-DRH-PMF, 2014 U.S. [read post]
24 Jan 2007, 5:24 pm
Okay, folks, we're signing off for now. [read post]
18 Jan 2007, 12:26 pm
(And in case you're wondering, no, STB did not reject me.) [read post]
20 Nov 2009, 5:10 pm
Commenting on my Bruce Bartlett post, Anonymous asks: Can you recommend a book on Keynesian economics suitable for an adult with a financial services background and an MBA? [read post]
24 Sep 2015, 5:24 am
  We’ve also noticed that, in the two years since Bartlett added the most significant piece to this puzzle, there’s hardly any case law on point – only one decision, In re DePuy Orthopaedics, Inc. [read post]
19 Aug 2013, 10:20 am by Bexis
The recent decision in In re Fosamax Products Liability Litigation, 2013 WL 4306434 (S.D.N.Y. [read post]
30 Apr 2014, 10:11 am
Thanks to Terry Henryat Blank Rome for sending along today’s preemption decision in In re Fosamax (Alendronate Sodium) Products Liability Litigation (No. [read post]